Lipid Management in the Geriatric Patient

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 1, 2009, Pages 185-206

  Nair, Ajith P ^a   Darrow, Bruce ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Cholesterol; Elderly; Ezetimibe; Fibrates; Geriatric; Lipids; Niacin; Statins

Indexed keywords

AMIODARONE; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CYCLOSPORIN; DILTIAZEM; DOCOSAHEXAENOIC ACID; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; PYRROLE DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERAPAMIL;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GERIATRIC CARE; GERIATRIC PATIENT; GLOMERULUS FILTRATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIVER FUNCTION; LIVER TOXICITY; LONG TERM CARE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; RASH; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; STROKE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS;

AGED; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CLOFIBRIC ACID; CORONARY DISEASE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; RISK FACTORS;

EID: 59649105697     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2008.11.003     Document Type: Review

References (100)

1. US Census Bureau. State and national population projections. Available at:. http://www.census.gov/population/www/projections/popproj.html Accessed June 2, 2008
2. Williams M.A., Fleg J.L., Ades P.A., et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or =75 years of age): an American Heart Association scientific statement from The Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, And Prevention. Circulation 105 14 (2002) 1735-1743
3. Ko D.T., Mamdani M., and Alter D.A. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 291 15 (2004) 1864-1870
4. Malenka D.J., and Baron J.A. Cholesterol and coronary heart disease. The importance of patient-specific attributable risk. Arch Intern Med 148 10 (1988) 2247-2252
5. Grundy S.M., Cleeman J.I., Rifkind B.M., et al. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 159 15 (1999) 1670-1678
6. Maroo B.P., Lavie C.J., and Milani R.V. Efficacy and safety of intensive statin therapy in the elderly. Am J Geriatr Cardiol 17 2 (2008) 92-100
7. Shepherd J. Monotherapy vs combination therapy for dyslipidemia in the elderly. Am J Geriatr Cardiol 17 2 (2008) 108-113
8. Kronmal R.A., Cain K.C., Ye Z., et al. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 153 9 (1993) 1065-1073
9. Krumholz H.M., Seeman T.E., Merrill S.S., et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 272 17 (1994) 1335-1340
10. Corti M.C., Guralnik J.M., Salive M.E., et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 126 10 (1997) 753-760
11. Frost P.H., Davis B.R., Burlando A.J., et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation 94 10 (1996) 2381-2388
12. Onder G., Landi F., Volpato S., et al. Serum cholesterol levels and in-hospital mortality in the elderly. Am J Med 115 4 (2003) 265-271
13. Schatz I.J., Masaki K., Yano K., et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 358 9279 (2001) 351-355
14. Kalantar-Zadeh K., Block G., Horwich T., et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 43 8 (2004) 1439-1444
15. Tiyyagura S.R., and Smith D.A. Standard lipid profile. Clin Lab Med 26 4 (2006) 707-732
16. Kreisberg R.A., and Kasim S. Cholesterol metabolism and aging. Am J Med 82 1B (1987) 54-60
17. Ferrara A., Barrett-Connor E., and Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation 96 1 (1997) 37-43
18. Choi B.G., Vilahur G., Viles-Gonzalez J.F., et al. The role of high-density lipoprotein cholesterol in atherothrombosis. Mt Sinai J Med 73 4 (2006) 690-701
19. Castelli W.P., Wilson P.W., Levy D., et al. Cardiovascular risk factors in the elderly. Am J Cardiol 63 16 (1989) 12H-19H
20. Florvall G., Basu S., and Larsson A. Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men. J Gerontol A Biol Sci Med Sci 61 12 (2006) 1262-1266
21. Lagakos S.W. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 354 16 (2006) 1667-1669
22. Wang R., Lagakos S.W., Ware J.H., et al. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 357 21 (2007) 2189-2194
23. Dornbrook-Lavender K.A., Roth M.T., and Pieper J.A. Secondary prevention of coronary heart disease in the elderly. Ann Pharmacother 37 12 (2003) 1867-1876
24. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 25 (2002) 3143-3421
25. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 8934 (1994) 1383-1389
26. Miettinen T.A., Pyorala K., Olsson A.G., et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 96 12 (1997) 4211-4218
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 9326 (2002) 7-22
28. Farmer J.A., and Gotto Jr. A.M. The Heart protection study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol 92 1A (2003) 3i-9i
29. Collins R., Armitage J., Parish S., et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 9411 (2004) 757-767
30. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events trial investigators. N Engl J Med 335 14 (1996) 1001-1009
31. Lewis S.J., Moye L.A., Sacks F.M., et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 129 9 (1998) 681-689
32. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 339 19 (1998) 1349-1357
33. Hunt D., Young P., Simes J., et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 134 10 (2001) 931-940
34. Sacks F.M., Tonkin A.M., Shepherd J., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 102 16 (2000) 1893-1900
35. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 20 (1995) 1301-1307
36. Allen Maycock C.A., Muhlestein J.B., Horne B.D., et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol 40 10 (2002) 1777-1785
37. Afilalo J., Duque G., Steele R., et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol 51 1 (2008) 37-45
38. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 20 (1998) 1615-1622
39. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 9435 (2004) 685-696
40. Neil H.A., DeMicco D.A., Luo D., et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 29 11 (2006) 2378-2384
41. Lemaitre R.N., Psaty B.M., Heckbert S.R., et al. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med 162 12 (2002) 1395-1400
42. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 9346 (2002) 1623-1630
43. Bjerre L.M., and LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 110 9 (2001) 716-723
44. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 13 (2001) 1711-1718
45. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 15 (2004) 1495-1504
46. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 14 (2005) 1425-1435
47. Waters D.D., Schwartz G.G., Olsson A.G., et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106 13 (2002) 1690-1695
48. Olsson A.G., Schwartz G.G., Szarek M., et al. Effects of high-dose atorvastatin in patients > or = 65 years of age with acute coronary syndrome (from the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering [MIRACL] study). Am J Cardiol 99 5 (2007) 632-635
49. Ray K.K., Bach R.G., Cannon C.P., et al. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J 27 19 (2006) 2310-2316
50. Wenger N.K., Lewis S.J., Herrington D.M., et al. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 147 1 (2007) 1-9
51. Deedwania P., Stone P.H., Bairey Merz C.N., et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 115 6 (2007) 700-707
52. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92 2 (2003) 152-160
53. Foody J.M., Shah R., Galusha D., et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113 8 (2006) 1086-1092
54. Ray J.G., Gong Y., Sykora K., et al. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 165 1 (2005) 62-67
55. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 22 (2007) 2248-2261
56. Masoudi F.A. Statins for ischemic systolic heart failure. N Engl J Med 357 22 (2007) 2301-2304
57. Crouse III J.R., Raichlen J.S., Riley W.A., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 297 12 (2007) 1344-1353
58. Ballantyne C.M., Raichlen J.S., Nicholls S.J., et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography. A study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 117 (2008) 2458-2466
59. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 13 (2006) 1556-1565
60. Ridker P.M. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108 19 (2003) 2292-2297
61. Hohl C.M., Dankoff J., Colacone A., et al. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 38 6 (2001) 666-671
62. Kaufman D.W., Kelly J.P., Rosenberg L., et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287 3 (2002) 337-344
63. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 11 (2004) 1307-1316
64. Bernick C., Katz R., Smith N.L., et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 65 9 (2005) 1388-1394
65. Jick H., Zornberg G.L., Jick S.S., et al. Statins and the risk of dementia. Lancet 356 9242 (2000) 1627-1631
66. Rockwood K., Kirkland S., Hogan D.B., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59 2 (2002) 223-227
67. Zandi P.P., Sparks D.L., Khachaturian A.S., et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County study. Arch Gen Psychiatry 62 2 (2005) 217-224
68. Li G., Higdon R., Kukull W.A., et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63 9 (2004) 1624-1628
69. Simons M., Keller P., De Strooper B., et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 95 11 (1998) 6460-6464
70. Sparks D.L., Sabbagh M.N., Connor D.J., et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62 5 (2005) 753-757
71. Klein R., Knudtson M.D., and Klein B.E. Statin use and the five-year incidence and progression of age-related macular degeneration. Am J Ophthalmol 144 1 (2007) 1-6
72. McGwin Jr. G., Modjarrad K., Hall T.A., et al. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study. Arch Ophthalmol 124 1 (2006) 33-37
73. Cukras CA, Agron E, SanGiovanni JP, et al. The use of statins and the development of AMD in AREDS [abstract 3772]. Association for Research in Vision and Ophthalmology 2008 Annual Meeting. Ft Lauderdale, FL; 2008.
74. Kastelein J.J., Akdim F., Stroes E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 14 (2008) 1431-1443
75. Lipka L., Sager P., Strony J., et al. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 21 15 (2004) 1025-1032
76. Rubins H.B., Robins S.J., Iwane M.K., et al. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 71 1 (1993) 45-52
77. Goldbourt U., Behar S., Reicher-Reiss H., et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 71 11 (1993) 909-915
78. The Coronary Primary Prevention trial: design and implementation: the Lipid Research Clinics Program. J Chronic Dis 32 9-10 (1979) 609-631
79. Manttari M., Elo O., Frick M.H., et al. The Helsinki Heart Study: basic design and randomization procedure. Eur Heart J 8 Suppl I (1987) 1-29
80. Scott R., Best J., Forder P., et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 4 (2005) 13-22
81. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 9500 (2005) 1849-1861
82. Buse J.B., Bigger J.T., Byington R.P., et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 99 12A (2007) 21i-33i
83. Birjmohun R.S., Hutten B.A., Kastelein J.J., et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 2 (2005) 185-197
84. Davidson M.H., Armani A., McKenney J.M., et al. Safety considerations with fibrate therapy. Am J Cardiol 99 6A (2007) 3C-18C
85. Holoshitz N., Alsheikh-Ali A.A., and Karas R.H. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. Am J Cardiol 101 1 (2008) 95-97
86. Guay D.R. Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother 33 10 (1999) 1083-1103
87. Rindone J.P., and Keng H.C. Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia. Chest 114 2 (1998) 641-642
88. Aldridge M.A., and Ito M.K. Fenofibrate and warfarin interaction. Pharmacotherapy 21 7 (2001) 886-889
89. Ahmad S. Gemfibrozil interaction with warfarin sodium (Coumadin). Chest 98 4 (1990) 1041-1042
90. Taylor A.J., Sullenberger L.E., Lee H.J., et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 23 (2004) 3512-3517
91. Goldberg R.B., and Jacobson T.A. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 83 4 (2008) 470-478
92. Bays H.E. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 99 6A (2007) 35C-43C
93. Davidson M.H., Stein E.A., Bays H.E., et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 29 7 (2007) 1354-1367
94. Nambi V., and Ballantyne C.M. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol 98 4A (2006) 34i-38i
95. Gruppo Italiano per lo Studio della Sporavvivenza nell'Infarto Miocardico - Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999) 447-455
96. Marchioli R., Barzi F., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sporavvivenza nell'Infarto Miocardico (GISSI)-prevenzione. Circulation 105 (2002) 1897-1903
97. Freund-Levi Y., Eriksdotter-Jonhagen M., Cederholm T., et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63 10 (2006) 1402-1408
98. Harris W.S. Expert opinion: omega-3 fatty acids and bleeding-cause for concern?. Am J Cardiol 99 6A (2007) 44C-46C
99. Benner J.S., Glynn R.J., Mogun H., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 4 (2002) 455-461
100. Nichols G.A., Nag S., and Chan W. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am Heart J 154 3 (2007) 554-560